Fady Ibraham Malik, EVP Research & Development at CYTOKINETICS INC (CYTK), sold 2,200 shares at $61.24 ($135K) on 2025-12-16, disclosed to the SEC on 2025-12-16.
Scheduled sale ($135k) by EVP Research & Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CYTK | SELL | 2026-09-08 | $264K | — | Filing → |
| CYTK | SELL | 2026-08-18 | $265K | — | Filing → |
| CYTK | SELL | 2026-07-23 | $282K | — | Filing → |